PDE3A and depressive symptom measurement: Although the role of PDE3A in the pathophysiology of MDD is not well established, this enzyme may be implicated in depressive symptoms, since cilostazol, a PDE 3A inhibitor, has been reported to decrease the severity of depressive symptoms assessed by Hamilton depression rating scale scores in poststroke depression patients [44].